Apogee Therapeutics to Participate in Upcoming Conferences

November 3, 2025

SAN FRANCISCO and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences.

Guggenheim 2nd Annual Healthcare Innovation Conference
Date: Tuesday, November 11, 2025
Fireside Chat Time: 1:30 p.m. ET

Stifel 2025 Healthcare Conference
Date: Wednesday, November 12, 2025
Fireside Chat Time: 11:20 a.m. ET

TD Cowen Immunology and Inflammation Virtual Summit
Date: Thursday, November 13, 2025
Fireside Chat Time: 12:30 p.m. ET

Jefferies London Healthcare Conference
Date: Wednesday, November 19, 2025
Fireside Chat Time: 3:00 p.m. GMT / 10:00 a.m. ET

Citi 2025 Global Healthcare Conference
Date: Wednesday, December 3, 2025
Fireside Chat Time: 9:45 a.m. ET

A live and archived webcast of the fireside chats will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.

About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest I&I markets, including for the treatment of Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), Chronic Obstructive Pulmonary Disease (COPD), and other I&I indications. Apogee's antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the Company's most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class profiles through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the Company believes it can deliver value and meaningful benefit to patients underserved by today's standard of care.

Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com

Media Contact:
Dan Budwick
1AB
dan@1abmedia.com